ID
42024
Description
Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.
Keywords
Versions (4)
- 7/6/15 7/6/15 -
- 8/6/15 8/6/15 -
- 3/15/21 3/15/21 - Dr. rer. medic Philipp Neuhaus
- 9/20/21 9/20/21 -
Uploaded on
March 15, 2021
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment
Previous and current therapies for leukemia
Description
STEM CELL TRANSPLANT
Alias
- UMLS CUI-1
- C1504389
Description
PRIOR RADIOTHERAPY FOR LEUKEMIA
Alias
- UMLS CUI-1
- C1522449
- UMLS CUI-2
- C0023418
Description
EXTERNAL DATA TRACKING
Alias
- UMLS CUI-1
- C1516800
Description
PRE-TREATMENT MUTATION ANALYSIS
Data type
boolean
Alias
- UMLS CUI-1
- C0796357
Description
DATE OF PRE- TREATMENT MUTATION ANALYSIS
Data type
date
Alias
- UMLS CUI-1
- C0011008
Description
PRE-TREATMENT LAB
Data type
boolean
Alias
- UMLS CUI-1
- C1527021
- UMLS CUI-2
- C1948041
- UMLS CUI-3
- C0022877
Description
Date of pre-treatment lab
Data type
date
Alias
- UMLS CUI-1
- C0011008
Similar models
Previous and current therapies for leukemia
C0023418 (UMLS CUI-2)
C1707479 (UMLS CUI-2)
C0023418 (UMLS CUI-2)
C1707479 (UMLS CUI-2)
C1948041 (UMLS CUI-2)
C0022877 (UMLS CUI-3)